COO Stock Analysis: The Cooper Companies | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 13.923m USD | 12M Return: 1.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 246M
EPS Trend: 34.9%
Qual. Beats: 1
Rev. Trend: 99.5%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Cooper Companies, Inc. (NASDAQ: COO) is a U.S.-based, large-cap healthcare supplies company headquartered in San Ramon, California, founded in 1958 and publicly traded since 1983. It operates through two segments: CooperVision, which designs, manufactures, and markets a range of contact lenses-including spherical, toric, and multifocal products addressing conditions such as astigmatism, presbyopia, and myopia-and CooperSurgical, which serves the family and womens healthcare market with products and services spanning fertility, medical devices, contraception, and cryostorage (including cord blood and tissue storage). Notable offerings within CooperSurgical include the Paragard hormone-free intrauterine device, fertility consumables and equipment, donor gamete services, and genomic/genetic testing. The company sells through a diversified channel network that includes distributors, group purchasing organizations, eye care and health care professionals, independent practices, corporate retailers, hospitals and clinics, and authorized resellers.
The contact lens business follows a recurring-revenue model driven by the disposable replacement cycle, and the global market for soft contact lenses is an oligopoly dominated by a small group of manufacturers. CooperSurgical operates in the womens health and fertility care space, an area supported by long-term demographic trends such as rising maternal age and growing demand for assisted reproductive services.
- CooperVision myopia management lens adoption drives segment growth
- CooperSurgical fertility and Paragard revenue offsets lens softness
- Strong dollar FX headwinds pressure international operating margins
| Net Income: 235.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.61 > 1.0 |
| NWC/Revenue: 11.70% < 20% (prev 27.91%; Δ -16.21% < -1%) |
| CFO/TA 0.08 > 3% & CFO 953.0m > Net Income 235.8m |
| Net Debt (2.32b) to EBITDA (865.9m): 2.68 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.0m) vs 12m ago -2.84% < -2% |
| Gross Margin: 64.37% > 18% (prev 67.20%; Δ -2.83% > 0.5%) |
| Asset Turnover: 33.99% > 50% (prev 32.13%; Δ 1.86% > 0%) |
| Interest Coverage Ratio: 5.17 > 6 (EBIT TTM 481.2m / Interest Expense TTM 93.1m) |
| A: 0.04 (Total Current Assets 2.30b - Total Current Liabilities 1.80b) / Total Assets 12.5b |
| B: 0.62 (Retained Earnings 7.70b / Total Assets 12.5b) |
| C: 0.04 (EBIT TTM 481.2m / Avg Total Assets 12.4b) |
| D: 1.94 (Book Value of Equity 8.24b / Total Liabilities 4.24b) |
| Altman-Z'' = 4.57 = AA |
| DSRI: 0.98 (Receivables 809.2m/780.9m, Revenue 4.23b/3.99b) |
| GMI: 1.04 (GM 67.20% / 64.37%) |
| AQI: 0.96 (AQ_t 0.64 / AQ_t-1 0.67) |
| SGI: 1.06 (Revenue 4.23b / 3.99b) |
| TATA: -0.06 (NI 235.8m - CFO 953.0m) / TA 12.5b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 05, 2026, the stock is trading at USD 74.20 with a total of 3,259,700 shares traded. Over the past week, the price has changed by +5.04%, over one month by +22.97%, over three months by +5.56% and over the past year by +1.23%.
Current recommended Stop Loss: 71.20 (which is 4% or 1.6 ATR below the current price).
The Cooper Companies has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy COO.
- StrongBuy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 80.6 | 8.6% |
P/E Trailing = 60.5
P/E Forward = 15.361
P/S = 3.3055
P/B = 1.6973
P/EG = 0.7141
Revenue TTM = 4.23b USD
EBIT TTM = 481.2m USD
EBITDA TTM = 865.9m USD
Long Term Debt = 1.86b USD (from longTermDebt, last quarter)
Short Term Debt = 598.9m USD (from shortTermDebt, last quarter)
Debt = 2.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.50m
Net Debt = 2.32b USD (calculated: Debt 2.46b - CCE 138.8m)
Enterprise Value = 16.2b USD (13.9b + Debt 2.46b - CCE 138.8m)
Interest Coverage Ratio = 5.17 (Ebit TTM 481.2m / Interest Expense TTM 93.1m)
EV/FCF = 28.53x (Enterprise Value 16.2b / FCF TTM 569.5m)
FCF Yield = 3.51% (FCF TTM 569.5m / Enterprise Value 16.2b)
FCF Margin = 13.46% (FCF TTM 569.5m / Revenue TTM 4.23b)
Net Margin = 5.57% (Net Income TTM 235.8m / Revenue TTM 4.23b)
Gross Margin = 64.37% ((Revenue TTM 4.23b - Cost of Revenue TTM 1.51b) / Revenue TTM)
Gross Margin QoQ = 68.00% (prev 67.88%)
Tobins Q-Ratio = 1.30 (Enterprise Value 16.2b / Total Assets 12.5b)
Interest Expense / Debt = 3.78% (Interest Expense 93.1m / Debt 2.46b)
Taxrate = 42.84% (176.7m / 412.5m)
NOPAT = 275.1m (EBIT 481.2m * (1 - 42.84%))
Current Ratio = 1.27 (Total Current Assets 2.30b / Total Current Liabilities 1.80b)
Debt / Equity = 0.30 (Debt 2.46b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.68 (Net Debt 2.32b / EBITDA 865.9m)
Debt / FCF = 4.08 (Net Debt 2.32b / FCF TTM 569.5m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.89% (Net Income 235.8m / Total Assets 12.5b)
RoE = 2.84% (Net Income TTM 235.8m / Total Stockholder Equity 8.30b)
RoCE = 4.74% (EBIT 481.2m / Capital Employed (Equity 8.30b + L.T.Debt 1.86b))
RoIC = 2.47% (NOPAT 275.1m / Invested Capital 11.1b)
WACC = 6.04% (E(13.9b)/V(16.4b) * Re(6.73%) + D(2.46b)/V(16.4b) * Rd(3.78%) * (1-Tc(0.43)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -31.46 | Cagr: -1.10%
[DCF] Terminal Value 77.97% ; FCFF base≈488.1m ; Y1≈559.5m ; Y5≈823.4m
[DCF] Fair Price = 51.62 (EV 12.4b - Net Debt 2.32b = Equity 10.1b / Shares 195.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 34.90 | EPS CAGR: 3.40% | SUE: 0.85 | # QB: 1
Revenue Correlation: 99.54 | Revenue CAGR: 6.75% | SUE: 3.79 | # QB: 1
EPS current Quarter (2026-07-31): EPS=1.12 | Chg30d=-5.89% | Revisions=-82% | Analysts=15
EPS current Year (2026-10-31): EPS=4.63 | Chg30d=+0.24% | Revisions=+25% | GrowthEPS=+12.3% | GrowthRev=+5.2%
EPS next Year (2027-10-31): EPS=5.00 | Chg30d=-0.48% | Revisions=-40% | GrowthEPS=+8.0% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -45% (up=9, down=26)